Ophthalmic company VSY Biotechnology announced that its research center has developed a new drug, TR-C 19, to treat COVID-19.
Studies have shown that TR-C 19 can neutralize the virus isolated under laboratory conditions, according to a company news release. The drug is now at the authority approval stage and is now ready for human testing.
Clinical and voluntary trials will be organized in partnership with Turkey’s Health Sciences University (SBU). The initial results of voluntary patient trials will be shared publicly in the coming weeks.
“At VSY Biotechnology, we have completed many pioneering R&D projects by producing new technologies thanks to our R&D team and innovation power. Our TR-C 19 project is one of the most meaningful projects that we have been developing,” Dr. Ercan Varlibas, Chairman of the Board of Directors of VSY Biotechnology, said in the news release.